SKYE (skyebioscience.com) Business Value to Revenue

Skye Bioscience, Inc. (SKYE) - corporate logo

The EV/Revenue ratio reflects the business valuation trend, where 0.00 serves as the current parameter value. Skye Bioscience, Inc. (SKYE) develops selective treatments for glaucoma and obesity, leveraging its existing liquidity reserves. However, the startup is gradually burning through capital raised from investors to cover clinical expenses. Risks include potential drug side effects and legal complexities regarding the use of compounds.

Skye Bioscience, Inc. (SKYE) - EV/Sales Multiple from 11/23/2025 to 11/20/2026

SKYE (skyebioscience.com): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:Skye Bioscience, Inc.
Core merchandise of Skye Bioscience, Inc.

Investing in the biotechnology sector requires a deep analysis of fundamental multiples. This indicator compares the total enterprise value to sales volume, excluding the impact of leverage to provide an objective assessment of market value. By analyzing the EV/Sales history, an investor determines the degree of asset overvaluation. For Skye Bioscience, Inc. (SKYE), this parameter reflects the market value of its unique developments in synthetic cannabinoids. Low values confirm the high investment attractiveness of the company's capital.